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Although there is much evidence to indicate that the magnitude of the antibody 
response to the capsular polysaccharide of t)~pe III Streptococcus pneumoniae (SSS- 
III) a is  regulated  by suppressor  as well as amplifier  T  lymphocytes (1-7),  the 
phenomenon  of low-dose paralysis  provides  an  ideal  experimental  model  for 
examining the properties of suppressor T  cells and their interaction  with other 
lymphoid cells engaged in the immune response.  In this antigen-specific T-cell- 
dependent form of unresponsiveness,  which persists for several weeks after its 
induction, mice pretreated (primed) with a single subimmunogenic dose of SSS- 
III  make a  greatly  reduced antibody response  upon subsequent immunization 
with an  optimally immunogenic  dose of antigen  (3,  6,  8).  Recent studies  have 
shown that low-dose paralysis to SSS-III can be transferred with spleen cells from 
primed  mice  (4);  the  transfer  of such  suppression,  which  likewise is  antigen- 
specific, requires Thy-1 ÷, Lyt-l-, 2 ÷, I-J  + lymphocytes (5). 
The mechanism(s) by which suppressor T  cells are activated in mice immunized 
or primed with SSS-III has not yet been defined.  However, we have proposed, 
based on the results of previous studies, that suppressor T  cells are activated in 
response to the idiotypic determinants  of B-cell-associated antibody specific for 
SSS-III (6, 7). If this is indeed the case, it should be possible to induce significant 
suppression with B cells transferred from mice either primed or immunized with 
SSS-III; the kinetics for the induction  and expression of such unresponsiveness 
should resemble those noted for the phenomenon of low-dose paralysis. Also, it 
should be possible to transfer suppression with T  lymphocytes after it has been 
induced by immune B cells. The present study was designed to provide experi- 
mental evidence in support of this hypothesis. 
Materials and Methods 
Mice.  Female BALB/cCum mice (8-10 wk of age), obtained from Cumberland View 
Farms, Clinton,  TN, were used throughout this work. 
* Supported in part through funds available from the National Institute of Allergy and Infectious 
Diseases, National Institutes of Health, Contract 263-80-D-0394. 
1  Abbreviations  used in this  paper: C', complement; GAMIg, goat anti-mouse immunoglobulin; HBSS, 
Hanks' Balanced Salt Solution; lg  ÷, immunoglobulin bearing; Ig-, nonimmunoglobulin bearing; PFC, 
plaque-forming cell; SRBC, sheep erythrocytes; SSS-III, type Ill pneumococcal  polysaccharide. 
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Antigen and Immunization Procedure.  The immunological properties of the preparations 
of SSS-III and dextran B-1355 used, as well as the method by which they were prepared 
have been described (3,  8-12).  Mice were given (i.p.)  appropriate doses of SSS-III or 
dextran B-1355 in 0.5 ml saline as stated in the text. 
Immunologic Methods.  Numbers of antibody-producing plaque-forming cells (PFC) spe- 
cific for SSS-III provided a measure of the magnitude of the antibody response produced 
at peak, i.e., 5 d after immunization with an optimally immunogenic dose (0.5 ~g) of SSS- 
III. PFC making antibody of the IgM class (>90% of all PFC [9, 11 ]) were detected by a 
slide version of the  technique of localized hemolysis-in-gel (8,  10-12) using indicator 
sheep erythrocytes (SRBC) sensitized with SSS-III by the CrCls method (13). PFC making 
antibody specific for dextran B-1355 were detected by a similar procedure (12) 5 d after 
immunization (i.p.) with an optimally immunogenic dose (100 ug) of this antigen. In all 
cases, corrections were made by subtraction for numbers of background SRBC-specific 
PFC found (<200 PFC per spleen) so that only PFC making antibody specific for SSS-III 
or dextran B-1355 are considered in this work. The values obtained (PFC per spleen), 
which are log-normally distributed (14), are expressed as the geometric mean of the log10 
number of PFC  per  spleen  for groups of similarly treated  mice;  this also provides a 
reasonably good measure of the total antibody response produced (15). Previous studies 
have shown that SSS-III and dextran B-1355, both of which are helper T-cell-independent 
polysaccharide antigens, do not cross-react serologically and that immunization with one 
antigen does not influence the magnitude of the antibody response to the other (12). 
Student's t-test was used to assess the significance of the differences observed. Differ- 
ences were considered to be significant when probability (P) values <0.05, were obtained. 
Treatment of Cells with Monoclonal Antibodies.  Monoclonal antibodies specific for Lyt- 
2.2 (NEI-006) or Thy-1.2 (NEI-001 A) mouse lymphocyte surface antigens were purchased 
from New England Nuclear, Boston, MA.  The procedure used for treating spleen cells 
with these monoclonal antibodies in the presence of complement (C'), as well as infor- 
mation concerning their specificity and immunologic characteristics, have been given (4). 
In all cell transfer experiments, mice were injected (i.v.) with known numbers of antibody- 
treated cells in a volume of 0.2 ml Medium 199. 
Isolation of Spleen Cells by the Plate-separation Procedure.  Immunoglobulin-bearing (lg+), 
as well as nonimmunoglobulin-bearing (Ig-) cells, were recovered from spleen cell suspen- 
sions  by the plate-separation method of Wysocki and Sato (16).  Here, affinity-purified 
goat anti-mouse Ig antibody (GAMIg; 0.5 mg protein/ml) was used. The specificity and 
method of preparation of GAMIg, which contains anti-IgG1, -IgG2A, -IgG2B in equal 
proportions, have been described (17). GAMIg was diluted (1:10) in 0.05 M Tris, pH 9.5, 
and 10 ml of the resulting solution were poured onto plastic petri plates (100 mm x  15 
mm;  Fisher Scientific Co.,  Silver Spring,  MD).  The plates were held for  1 h  at room 
temperature and then overnight at 4°C; they were washed extensively with phosphate- 
buffered saline, pH 7.4, just before use. 
Suspensions of spleen cells in Hanks' Balanced Salts Solution (HBSS) first were treated 
with ACK lysing buffer (18) to eliminate intact erythrocytes. The remaining cells were 
washed five times with HBSS and resuspended to a final density of 107 nucleated cells/ 
ml in Medium 199. Then, 10 ml of cell suspension were added to petri plates coated with 
affinity-purified GAMIg antibody. The plates were kept stationary at 4°C for 40 min, 
after which they were swirled gently to redistribute unattached cells and held at 4°C for 
30 min; then, the remaining unattached (Ig-) cells were decanted. 
In order to recover adherent (Ig  +) spleen cells from the plates, the procedure described 
above was modified slightly in that the plates were coated beforehand with a 1:50, rather 
then  1:10,  dilution of affinity-purified GAMIg antibody.  After unattached  cells  were 
decanted, the plates were washed gently (four times) with  HBSS. Then,  5  ml of 10% 
normal mouse serum in HBSS was added to each plate. After the plates were held for 2- 
4  min  at  room  temperature (25°C)  the  attached  (Ig  ÷) cells  became  loose;  they were 
recovered by rinsing the plates several times with HBSS. 
The purity of the  cell suspensions recovered by the plate-separation procedure was 
assessed by fluorescence-activated cell sorter analysis (Becton Dickinson FACS-II System, TAYLOR  ET  AL.  705 
Mountain View, CA); details concerning the reagents and procedures used for this purpose 
have been given elsewhere (19).  In the experiments to be described, the nonadherent cell 
suspension used was found to contain <2% Ig  ÷ and 96% Thy-l.2  + cells; the adherent cell 
suspensions contained >97 % Ig  ÷ cells.  For convenience, these will be referred to as plate- 
separated Ig- and Ig  ÷ cell suspensions, respectively. 
Isolation of Antigen-binding B  cells from  Suspensions of Immune  Spleen Cells.  Antigen- 
binding B cells specific for SSS-III were isolated by the adsorption, and then elution, of 
immune spleen cells from a  Sepharose 6MB column to which SSS-III had been bound 
covalently.  In order  to  prepare  the  column,  an  amino derivative of SSS-III first  was 
synthesized.  Here,  50  mg of SSS-III (10  mg/ml in  borate saline  buffer, pH  8.0)  was 
placed in a beaker kept in an ice bath. Then, 0.67 ml (0.1  mol) of anhydrous ethylenedi- 
amine and 0.25  ml of 0.1  M sodium metaperiodate were added with constant stirring. 
After 30  rain,  1.25  ml of 2.0  M  sodium borohydride was added  and the  mixture was 
stirred for I  h; at the end of this time period, the solution was dialyzed against several 
changes of borate saline buffer. The amino derivative of SSS-III was conjugated directly 
to cyanogen bromide (CNBr)-activated Sepharose 6MB (Pharmacia Chemicals, Piscataway, 
NJ), at a ratio of 11  mg SSS-III/ml of beads using a standard procedure for conjugating 
proteins to CNBr-activated Sepharose. The beads were washed extensively with several 
volumes of HBSS to remove all traces of unbound SSS-III. Also, a Sepharose 6MB column 
in which all reactive sites were blocked by the addition of excess 0.2 M glycine--in place 
of the amino derivative of SSS-III--was prepared for use as a specificity control (glycine- 
Sepharose-6MB). 
Spleen cells from mice immunized or primed with  SSS-III were  treated  with  ACK 
lysing buffer (18), washed (3x) with HBSS, and resuspended in Medium  199 at a density 
of 10 x  107 cells/ml. For the recovery of unbound cells,  1.5 ml of spleen cell suspension 
was applied to a column consisting of 6 ml of either SSS-III or glycine-coated Sepharose 
6MB beads in a  12-ml syringe. Then ~  10 drops of Medium 199 were added to allow the 
cells to perfuse further into the column. The column was incubated for 30 rain at 4°C; 
then the unbound cells were eluted (drop by drop) by the addition of 18 ml HBSS. For 
the recovery of bound  cells,  the  incubation  time was reduced  to  15  min at 4°C.  The 
column was washed free of all unbound cells with 50 ml HBSS. After a period of agitation 
in HBSS and allowing the beads to settle, the bound cells which then became loose were 
decanted. 
Preparation ofAmpl~er T Cells.  Mice were pretreated (primed) with a subimmunogenic 
dose (0.005 #g) of SSS-III. 3 d  later, spleen cell suspensions were prepared and treated 
with monoclonal anti-Lyt-2.2 antibody plus C' to remove suppressor T  cell activity (4). 
The resulting cell suspension has been shown to be a relatively rich source of amplifier T 
cell activity (5). 
Irradiation Procedure.  Mice were given whole body irradiation by exposure to a  ~7Ce 
source at a dose rate of 139 rads/min. 
Results 
Induction of Antigen-specific  Suppression  of the Antibody Response  with B  Cells from 
Mice Immunized with SSS-III.  Groups of 5-10 mice were given a  single injection 
(i.p.) of 0.5 ug SSS-III; 48 h  later, when few--if any--SSS-III-specific PFC can 
be detected (9), spleen cell suspensions were prepared from which adherent (Ig  ÷) 
cells were isolated by the plate-separation procedure.  Then,  known numbers of 
immune Ig  + cells were transferred (i.v.) to mice that were immunized (i.p.),  3  d 
later, with both 0.5 ~g SSS-III and  100 ug dextran B-1355; recipient mice were 
assayed  for  numbers  of  SSS-III-specific  and  dextran-specific  PFC  5  d  after 
immunization.  The  results  obtained  were  compared  with  those  of immunized 
mice not given Ig  + immune spleen cells, or those of immunized mice given Ig  + 
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dextran  B-1355. 
The data of Table I show that the transfer of 3.4 ×  106 Ig  ÷ spleen cells from 
mice immunized with SSS-III greatly reduced (P <0.05) the capacity of recipient 
mice to make an antibody response to an optimally immunogenic dose (0.5 #g) 
of SSS-III; the transfer of the same population of such cells had no effect upon 
the antibody response to dextran B-1355 (P >0.05). In another experiment, the 
transfer of Ig  + spleen cells from either nonimmunized  mice or mice immunized 
with dextran  B-1355 did not influence the capacity of recipient mice to make an 
antibody response to 0.5 #g SSS-III (P >0.05,  in both instances).  The transfer 
of similar numbers of Ig- spleen cells was without effect (data not shown). These 
findings indicate that the transfer of B cells from mice immunized with SSS-III 
suppresses the capacity of recipient  mice to make an antibody response to this 
antigen upon subsequent immunization. Since the suppression induced is antigen- 
specific, it is not an artifact of the procedure used to isolate Ig  + spleen cells. 
Ability to Induce Suppression  with  T-Cell-depleted Immune  Spleen  Cells.  Since it 
was difficult, as well as time-consuming, to obtain large numbers of adherent Ig  + 
immune spleen cells by the plate-separation procedure, we wished to determine 
whether  comparable  suppression  also  could  be  induced  with  T-cell-depleted 
immune spleen cells. Groups of 5-10 mice were given a single injection (i.p.) of 
0.5 #g SSS-III. Then, 48 h later, spleen cell suspensions were prepared that were 
either transferred  (i.v.)  directly to recipient  mice,  or treated  with  monoclonal 
anti-Tby-l.2 antibody +  C' before transfer; the latter treatment has been shown 
to eliminate effects likely to be produced by transferred suppressor and amplifier 
T  cells (4, 5). Recipients of transferred cells were immunized (i.p.) with both 0.5 
~g SSS-III and  100 #g dextran B-1355 3 d after cell transfer;  they were assayed 
for numbers of antigen-specific PFC 5 d after immunization. 
The  data  of Table  II  show  that  significient  (P  <0.05)  suppression  of the 
antibody  response  to  SSS-III  was induced  following the  transfer  of 20  ×  106 
TABLE  I 
Spec~city of Suppression Induced by B Cells  from Mice Immunized with SSS-III 
Expt.  Number and type of 
no.  B cells transferred 
PFC/spleen* vs. 
SSS-III  Dextran B-1355 
0  4.058 +  0.081 
(11,442) 
3.4 ×  106 cells*  3.744 ±  0.012 
(5,543) 
0  4.041  +  0.051 
(10,994) 
5 ×  106 cells  ~  4.014 ±  0.087 
(10,332) 
5 ×  106 cells  I  4.000 ±  0.082 
(10,000) 
4.613 +_ 0.038 
(41,042) 
4.696 _  0.099 
(49,685) 
* LOglo PFC per spleen ___ SEM for  10 mice, 5  d  after immunization (i.p.) with 0.5 t~g SSS-III and 
100 t~g dextran B-1355; geometric means are in parentheses. 
* Plate-separated, Ig  ÷ spleen cells from mice, 48 h after immunization (i.p.) with 0.5 ~g SSS-III. 
a Plate-separated, Ig  ÷ spleen cells from mice, 48 h  after immunization (i.p.) with  100 ug dextran B- 
1355. 
I Plate-separated, Ig  ÷ spleen cells from nonimmunized mice. TAYLOR  ET  AL. 
TABLE  II 
Induction of Suppression with T-Ceil-depleted Immune Spleen Cells 
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Number of  Treatment of trans-  PFC/spleen vs. 
cells trans-  ferred cells  ferred*  SSS-III  Dextran B-1355 
0  --  4.228 4- 0.053*  4.706 __. 0.069 
(16,916)  (50,829) 
20 ×  106  None  3.638 + 0.124  4.718 4- 0.061 
(4,347)  (52,254) 
20 ×  106  Anti-Thy-l.2 4- C'  3.310 4- 0.109 
(2,041) 
* Spleen cell suspensions were prepared for transfer, 48 h after donor mice were given (i.p.) 0.5 ~g 
SSS-III. 
* Logl0 PFC/spleen 4- SEM for groups of 10 mice, 5 d after immunization  (i.p.) with 0.5 gg SSS-III 
and 100 ug dextran B-1355; geometric  means are in parentheses.  Mice were immunized (i.p.) 3 d 
after the transfer of cells. 
TABLE  III 
Dose-response Relationships for the Induction of Suppression with T-Cell-depleted 
Immune Spleen Cells 
Number of cells  SSS-III-specific  Mean % 
transferred*  PFC/spleen  suppression 
0  4.253 __. 0.079*  -- 
(17,886) 
0.5 x  106  4.205 __- 0.060  10 
(16,030) 
2.5 ×  106  4.045 4- 0.076  38 
(11,081) 
5 ×  106  3.809 + 0.146  64 
(6,442) 
10 x  106  3.642 4- 0.179  76 
(4,387) 
20 x  106  3.509 __- 0.146  82 
(3,230) 
40 x  106  3.674 4- 0.115  74 
(4,725) 
* Spleen cell suspension, prepared 48 h after mice were given (i.p.) 0.5 gg SSS-III, were 
treated with anti-Thy-l.2 + C' as described. 
* LogJ0 PFC/spleen _+ SEM for groups of I0 mice, 5 d after immunization (i.p.) with 
0.5 gg SSS-III; geometric means are in parentheses.  Mice were immunized, 3 d after 
the transfer of cells. 
immune spleen cells, with or without treatment with monoclonal anti-Thy-l.2 + 
C'  before  cell  transfer;  such  suppression  was  antigen-specific since  the  same 
population of transferred cells did not influence the magnitude of the antibody 
response to dextran B-1355 (P >0.05). The degree of suppression induced with 
T-cell-depleted immune cells increased with the number of cells transferred and 
reached  maximal levels in mice given  10-40  ×  106 cells (Table III). Since the 
degree of suppression induced with 5  X  106 T-cell-depleted immune cells (64%) 
was similar to that obtained with  3.4  x  106 plate-separated Ig  + immune spleen 
cells (52%;  Table  I),  both  types of cell suspension appeared  to  be  comparable 708  ACTIVATION OF  SUPPRESSOR  T  CELLS 
with respect to their ability to induce antigen-specific suppression of the antibody 
response to SSS-III. 
The Induction of Suppression  by Transferred Immune Spleen  Cells Requires Antigen- 
binding B  Cells.  Spleen  cell  suspensions  were  prepared  from  mice 48  h  after 
immunization with 0.5 #g SSS-III. The cells were treated with ACK lysing buffer, 
to remove intact erythrocytes, and then monoclonal anti-Thy-l.2 antibody +  C' 
to inactivate T  cells. A portion of the resulting cell suspension, containing -~ 150 
×  106  nucleated  cells, was passed over a  6-ml Sepharose 6MB column to which 
either SSS-III or glycine had been bound  covalently.  Cells that  did not adhere 
to  the  column  (unbound  cells)  were  collected,  as  well  as  cells  recovered  by 
decantation after agitation and rapid settling of the beads (bound cells). Equiva- 
lent  numbers  of bound  and  unbound  cells,  as  well  as  cells  from  the  original 
unfractionated  cell  suspension,  then  were  transferred  (i.v.)  and  compared  for 
their ability to induce  suppression  of the  antibody response to  SSS-III in  mice 
immunized with 0.5 #g SSS-III 3 d  after cell transfer. 
The data of Table IV show that  5  ×  106 spleen cells that did not bind to the 
SSS-III  Sepharose  6MB  column  did  not  induce  suppression  of the  antibody 
response to SSS-III after transfer (P >0.05).  However, significant suppression (P 
<0.05) was induced after the transfer of 5  x  l0 p bound or 5  ×  106 bound  cells 
recovered  from  the  SSS-III-Sepharose 6MB  column  (P  <0.05  in  both  cases). 
When  the same cell suspension was passed through  the  glycine-Sepharose-6MB 
column,  significant  (P <0.05)  suppression  was induced  only with  the  unbound 
cell fraction.  It should be noted that the degree of suppression  induced by 5  × 
105  or  5  x  106  SSS-III-bound cells was similar to that  obtained with  20  ×  106 
unfractionated cells. The foregoing studies indicate that the capacity of immune 
spleen cells to induce suppression of the antibody response to SSS-III is dependent 
upon the presence of Ig  + cells capable of binding specifically to SSS-III. 
B  Cell-induced  Suppression  Is Not Due to Antibody-mediated  Feedback Inhibition or 
TABLE  IV 
Antigen-binding Cells are Required  for the Induction of Suppression 
Mean % sup- 
No. and type* of cells  pression after  Column used to isolate cells  transferred  transfer* 
SSS-IlI-Sepharose-6MB  5 X 106 Unbound  <7 -  4 
5 X 106 Bound  56 --. 8  ! 
5 X 105 Bound  54 __. 8 g 
1 x  105 Bound  34+5 
Glycine-Sepharose-6MB  5 × 106 Unbound  45 __. 110 
5 x  106 Bound  10 ± 7 
5 x  105 Bound  12 ± 5 
1 x  105 Bound  16±8 
I  20 × 106 Unfractionated  67 ±  10 
* Unfractionated  cells = original cell suspension, before passage through a Sepharose 6MB column; 
unbound  cells =  cells that did  not adhere to the Sepharose  6MB column; bound  cells =  cells 
recovered after adherence to the Sepharose 6MB column. Mice were immunized with 0.5 #g SSS- 
Ill 3 d after cell transfer, PFC/spleen for groups of 10 mice was determined  5 d after immunization, 
~t Calculated with respect to the control i.e. immunized mice not given immune spleen cells. 
0  Significant suppression (P<0.05). TAYLOR  ET  AL.  709 
Residual  Antigen.  Two  experimental  approaches  were  used  to  determine 
whether suppression  was  induced by antibody synthesized and released from 
transferred immune B ceils, i.e., antibody-mediated feedback inhibition (20). In 
the first, two groups of mice were immunized (i.p.) with 0.5 #g SSS-III. However, 
one group  was irradiated (1,000  rads) 48  h  later, just before the removal of 
spleens and the preparation of spleen cell suspensions; at this time, few, if any, 
PFC can be detected in the spleens of mice immunized with 0.5 #g SSS-III (9). 
Cell suspensions from both irradiated and nonirradiated mice were treated with 
monoclonal anti-Thy-l.2 antibody +  C'  before transfer (i.v.)  to recipient mice 
that were immunized (i.p.) with 0.5 #g SSS-III 3 d later. Recipients were assayed 
for SSS-III-specific PFC/spleen 5 d after immunization. 
The data of Table V show that significant suppression (P <  0.05) was induced 
after the transfer of either irradiated or nonirradiated spleen cells. It should be 
noted that treatment with only 250 rads of irradiation has been found to abolish 
completely the capacity of mice to make a detectable antibody response to SSS- 
III and that no serum antibody or SSS-III-specific PFC could be detected in the 
spleens of unimmunized  recipient mice after the transfer of irradiated immune 
spleen cells (data not shown). Earlier studies (21) have shown that large amounts 
of passively administration  high-titer  immune serum,  containing  much  more 
antibody than is likely to be produced under these circumstances, are required 
to demonstrate only a  modest degree, at best,  of antibody-mediated feedback 
inhibition; it is most unlikely that the suppression obtained is dependent upon 
the  containued  synthesis  and  release  of antibody  by  transferred  cells.  The 
administration of 1,000  rads X-irradiation also has been shown to abolish sup- 
pressor T  cell activity in cell transfer experiments (5). 
In the second experimental approach, donor mice were given a single injection 
(i.p.) of a subimmunogenic dose (0.005 #g) of SSS-III which, though capable of 
inducing low-dose paralysis, does not result in the production of detectable SSS- 
III-specific PFC or serum antibody (8); 48 h  later, spleen cell suspensions were 
prepared that were treated with monoclonal anti-Thy-l.2 antibody +  C' before 
TABLE  V 
Effect of Irradiation  (1,000 fads) on the Capacity of Transferred Immune Spleen 
Cells to Induce Suppression 
Number and type of  SSS-III-specific  Mean % 
cells transferred*  PFC/spteen*  suppression 
0  4.124 +  0.042  -- 
(13,308) 
20 X 106, irradiated  0  3.661 +  0.086  66 
(4,584) 
20 x  106, nonirradiated  3.365 +  0.104  83 
(2,315) 
* Spleen cell suspensions were prepared 48 h after immunization (i.p.) with 0.5 #g SSS- 
III; the cells were treated with monoclonal anti-Thy-l.2 +  C' before transfer. 
* Log~0 PFC/spleen +  SEM for groups of 10 mice, 5 d  after immunization (i.p.) with 
0.5/zg SSS-III; geometric means are in parentheses. Mice were immunized (i.p.) 3 d 
after cell transfer. 
Donor mice were irradiated (1,000 rads)just prior to removal of spleen, i.e.,  48  h 
after immunization (i.p.) with 0.5 ug SSS-III. 710  ACTIVATION  OF  SUPPRESSOR T  CELLS 
transfer to recipient mice. Recipients were immunized (i.p.) with 0.5 #g SSS-III, 
3 d after cell transfer and assayed for SSS-III-specific PFC 5 d after immunization. 
The data of Table VI show that significant (P <  0.05) suppression was induced 
after the transfer of spleen cells from mice given a subimmunogenic dose (0.005 
•g)  of SSS-III; in fact, the degree of suppression noted (78%) was at least as great 
as that obtained when suppression was induced with spleen cells from mice given 
an optimally immunogenic dose (0.5 #g) of SSS-III (Tables I-III). 
The results of other studies (22) have shown that >90% of the SSS-III used in 
this  work  is  excreted  from  the  body  within  48  h  after  immunization.  Also, 
convincing low-dose paralysis is not induced in mice primed with <0.001  #g of 
SSS-III  (23).  In  view  of  these  considerations  and  the  fact  that  spleen  cell 
suspensions are washed several times before transfer, it is extremely unlikely that 
the ability to induce suppression  with spleen cells from mice given a  subimmu- 
nogenic  dose  of SSS-III  (Table  VI)  is  due  to  residual  antigen  in  donor  cell 
suspensions. 
The Transfer of  hnmune B Cells Results in the Activation of  Suppressor T Cells.  Two 
types of experiments were conducted to determine whether transferred immune 
B cells act directly or indirectly to mediate the suppression observed.  The first 
experiment  involved an  examination  of the  kinetics for the  induction of sup- 
pression after the transfer of immune B  cells.  Donor mice were given a  single 
injection (i.p.) of 0.5 ~g SSS-III; 48 h later, spleen cell suspensions were prepared 
that were treated with monoclonal anti-Thy-l.2 antibody +  C' before transfer 
to recipient mice. Then  groups of recipients, which were given (i.v.)  10  ×  106 
immune cells, were immunized (i.p.) with 0.5 #g SSS-III at different times after 
cell transfer and the magnitude of the PFC response produced was assessed 5 d 
after immunization. The  values obtained were compared with those of immu- 
nized  mice not given  immune spleen cells  in  order  to calculate the degree  of 
suppression induced. The results obtained (Fig.  1) show that an inductive period 
of ~  16-24  h  is required  before  significant (P <0.05)  suppression  is  induced 
after cell  transfer.  Thereafter,  the  degree  of suppression  expressed  increases 
progressively  until  maximal  levels  are  obtained  48-72  h  after  cell  transfer; 
TABLE  VI 
Ability to Induce Suppression After the Transfer of Spleen Cells  from 
Mice Given a Subimmunogenic Dose (O.O05 #g) of SSS-III 
Number of cells  SSS-IlI-specific  Mean % 
transferred*  PFC/spleen*  suppression 
0  4.199 + 0.077  -- 
(15,822) 
20 × 108  3.510 _+ 0.162  78 
(3.510) 
* Spleen cell suspensions  were prepared 48 h after donor mice were given 
a single injection (i.p.) ofa subimmunogenic  dose (0.005 #g) of SSS-III; 
cell suspensions were treated with monoclonal anti-Thy-l.2 antibody + 
C' before transfer. 
* Log10 PFC/spleen __+ SEM for groups of 10 mice, 5 d after immunization 
(i.p.) with 0.5 ug SSS-III; geometric means  are in parentheses. Mice were 
immunized (i.p.) 3 d after the cell transfer. 100 
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FIGURE  1.  Kinetics for the induction of suppression of the PFC response to 0.5 #g SSS-III 
after the transfer of 10  X  106 immune B cells.  Values shown represent the mean degree of 
suppression _  SEM for groups of 10-24 mice. 
significant suppression is demonstrable for at least 6 wk after cell transfer. This 
kinetic pattern is similar to that noted for the induction of low-dose paralysis 
with a  subimmunogenic dose of SSS-III  (4).  The  latent period noted for the 
induction of suppression after the transfer of immune spleen cells suggests that 
B cells do not act directly to mediate the suppression observed. 
In the second type of experiment, a two-step cell transfer procedure was used 
to identify the type of cell responsible for mediating suppression after the transfer 
of immune B ceils. Donor mice were given a single injection (i.p.) of 0.5/~g SSS- 
III;  48  h  later,  spleen  cell  suspensions  were prepared  that  were treated with 
monoclonal anti-Thy-l.2  +  C'  before transfer to  recipient mice.  Then,  24  h 
after the transfer of immune B cells, spleen cell suspensions were prepared and 
10 x  106 T  cells, from the nonadherent fraction obtained by the plate-separation 
method (<2%  Ig  + and 96% Thy-l.2  ÷ cells), were transferred to another group 
of recipient mice that were immunized (i.p.) with 0.5/~g SSS-III at the time of T 
cell transfer (no inductive period allowed). Mice were assayed for SSS-IIl-specific 
PFC 5 d after immunization; the results obtained were compared with those of 
immunized mice not given T  cells derived from immune B-cell-primed mice. 
The data of Table VIII clearly show that significant (P <0.05) suppression was 
induced, without the need for an inductive period, in mice given T  cells from 
donors primed with immune B cells. Thus,  the suppression induced after the 
transfer of immune B cells is mediated by suppressor T  cells which are activated 
in response to immune B cells. 
Abrogation of B-cell-induced Suppression by Ampl~er  T  Cells.  The  results  of 
previous studies have shown that the antibody response to SSS-III is regulated 
by the competitive interaction of amplifier and suppressor T  cells (1, 2, 6); such 
regulatory T  cells, which differ with respect to their Lyt phenotype and kinetics 712  ACTIVATION  OF  SUPPRESSOR  T  CELLS 
TABLE  VII 
Suppression of the Antibody Response to SSS-III Afier the Transfer ofT Cells 
from Mice Given Immune B Cells 
Number and type of  SSS-III-specific  Mean % 
cells transferred*  PFC/spleen*  suppression 
0  4.206 ± 0.035  -- 
(16,062) 
10 ×  106 T cells  3.827 +_. 0.131  58 
(6,714) 
* T  cells, isolated by the plate-separation procedure, were obtained from mice 
24 h  after the transfer of 10  ×  106  immune B cells.  Immune  B cells were 
obtained 48 h after immunization (i.p.) with 0.5 ttg SSS-III; these cells were 
treated with monoclonal anti-Thy-l.2 + C' before transfer. 
* Log~0 PFC/spleen _  SEM for groups of l0 mice, 5 d after immunization (i.p.) 
with 0.5 pg SSS-III;  geometric means are in parentheses. Mice were immunized 
at the time of transfer of 10 x  108 T cells. 
TABLE  VIII 
Effect of Ampl~er T Cells on the Expression of Suppression Induced by Immune B Cells 
SSS-III-specific  Mean % 
Number and type of cells transferred*  PFC/spleen*  suppression 
0  4.185 + 0.072  -- 
(15,298) 
10 X 106 immune B cells  3,721  ± 0.165  66 
(5,257) 
10 X 106 immune B cells + 2.5 ×  106  4.332 ± 0.036  0 
amplifier T cells  (21,491) 
* Immune spleen cells were obtained 48 h after donor mice were immunized (i.p.) with 0.5 pg SSS- 
I I I and treated with monoclonal anti-Thy-1.2 + C' before transfer. Amplifier T cells were obtained 
72 h after donor mice were primed (i.p.)  with  0.005  #g SSS-III; these cells were treated with 
monoclonal anti-Lyt-2.2 antibody + C' before cell transfer. Amplifier cells were given at the time 
of immunization. 
* Log~0 PFC/spleen + SEM for groups of 10 mice, 5 d after immunization (i.p.) with 0.5 ttg SSS-III; 
geometric means are in parentheses. Mice were immunized 3 d after transfer of immune spleen 
cells. 
for activation, are known to have profound  influences on the results obtained in 
cell-transfer  experiments  (5).  Consequently,  we  wished  to  examine  whether 
amplifier T  cell activity could overcome the suppressive effects induced following 
the transfer of immune  B  cells. To  this end,  mice were given  10  ×  106 immune 
B  cells from  donor  mice  immunized  (i.p.),  2  d  earlier,  with  0.5  ~tg  SSS-III to 
induce suppression as described in the foregoing experiments. Amplifier T  cells 
were  obtained  from  another  group  of  mice  72  h  after  priming  (i.p.)  with  a 
subimmunogenic  dose  (0.005  #g)  of  SSS-III;  these  cells  were  treated  with 
monocional anti-Lyt-2.2 antibody +  C' before cell transfer to eliminate suppres- 
sor T  cell activity (5). 3 d  after cell transfer one-half of the mice were immunized 
(i.p.) with 0.5 #g SSS-III; the other half received 2.5 ×  106 amplifier T  cells (i.v.) 
along with  0.5  ttg  SSS-III. All mice  were  assayed for  SSS-III-specific PFC  5  d 
after immunization.  The  data of Table VIII show that significant suppression (P 
<0.05)  was induced after the transfer of immune  B  cells as expected. However, 
the transfer of amplifier T  cells completely eliminated the suppression  induced TAYLOR  ET  AL.  713 
(P <0.05); the resulting response, in fact, appeared to be greater (P <0.05) than 
that of immunized mice not given transfer cells. Aside from providing further 
evidence that suppression, which is reversible, is not due to antibody-mediated 
feedback inhibition, these findings further attest to the fact that amplifier and 
suppressor T  cells interact in a  competitive manner to regulate the magnitude 
of the antibody response to SSS-III. 
Discussion 
Since it was discovered that suppressor T  cells exert  their inhibitory effects 
not  only  during  the  course  of a  normal  antibody  response  to  an  optimally 
immunogenic dose of SSS-III  (1,  2),  but also after  the induction of low-dose 
paralysis to SSS-III (3, 8), much attention has been focused on the mechanism(s) 
by which suppressor T  cells become activated under these experimental condi- 
tions. Because the effects produced by suppressor T  cells involved in the antibody 
response to SSS-III are antigen-specific (4, 23), the direct activation of suppressor 
T  cells by antigen was the first possibility considered. However, the inability of 
SSS-III to elicit (a) T-cell-proliferative responses, (b) immunological memory, (c) 
helper T  cell effects, and (d) delayed hypersensitivity reactions, all of which are 
characteristic  of the  capacity  of T  cells  to  recognize and  respond  directly  to 
antigen, was inconsistent with such a concept (reviewed in reference 6). Conse- 
quently, we proposed that suppressor T  cells are  activated in response to the 
idiotypic determinants of B-cell-associated antibody specific for SSS-III (7); such 
a  recognition mechanism would provide an efficient means for regulating the 
magnitude of the antibody response with a  high degree of antigen specificity. 
The present work was designed to obtain experimental evidence in support of 
this hypothesis. The results obtained show that antigen-specific suppression of 
the  antibody  response  to  SSS-III  can  be  induced,  in  a  cell-dose-dependent 
manner, by the transfer of Ig  + spleen cells from mice previously immunized with 
an  optimally  immunogenic dose  (0.5  t~g) of SSS-III  (Tables  I  and  III).  The 
induction of such suppression is not dependent upon the transfer of suppressor 
T  cells activated by prior exposure to antigen; it can be induced using T-cell- 
depleted populations of immune spleen cells and requires the presence of Ig  +, 
antigen-binding cells from mice immunized with SSS-III (Tables I, II, and IV). 
These  findings  indicate  that  the  suppression  observed  is  induced  by  B  cells 
bearing cell-associated antibody specific for SSS-III. It is most unlikely that such 
suppression is due to antibody-mediated feedback inhibition (20) since the same 
degree of suppression could be induced using immune cells from donors irradi- 
ated before the appearance of detectable PFC or serum antibody, i.e., <48 h after 
immunization  (Table  V),  as  well  as  with  spleen  cells  from  mice  pretreated 
(primed) with a  subimmunogenic dose (0.005 #g) of SSS-III (Table VI); in the 
latter  case,  priming  with  the  subimmunogenic dose  used  does  not  elicit  the 
development  of  detectable  PFC  or  serum  antibody  specific  for  SSS-III  (8). 
Furthermore, suppression was abrogated  with the transfer of cell populations, 
rich in amplifier T  cell activity (Table VIII), a finding that is consistent with the 
results obtained in other cell-transfer studies (5). 
The kinetics for the induction of suppression after the transfer of immune B 
cells (Fig.  1) are virtually identical to those described for the in vivo induction of 714  ACTIVATION OF SUPPRESSOR T  CELLS 
low-dose paralysis to SSS-III (4).  In both cases, after a latent or inductive period 
of  --~16-24  h,  there  is  a  progressive  increase  in  the  degree  of suppression 
expressed until a maximal level is attained, 72 h after the transfer of immune B 
cells (Fig. 1) or priming with a subimmunogenic dose of SSS-III (4); once induced, 
suppression persists for several weeks. This kinetic pattern suggests that immune 
B cells may not be acting directly to mediate the suppression observed; instead, 
they may provide a signal or stimulus for the activation of suppressor T  cells that 
regulate the magnitude of the antibody response by limiting the extent to which 
antigen-stimulated B cells proliferate in response to SSS-III (24, 25). This indeed 
was found to be the case since T  cells taken from mice previously given immune 
B cells were found to produce significant suppression,  without the need for a 
latent period,  upon  transfer to  immunized mice (Table  VII).  These  findings 
clearly show that B-cell-associated antibody specific for SSS-III plays an instru- 
mental role in the activation of suppressor T  cells that regulate the magnitude 
of the antibody response to SSS-III. Because the suppression observed is antigen- 
specific (Tables I and II), we assume that the idiotypic determinants of antibody 
specific for SSS-III are the major recognition units involved in this process and 
are attempting to obtain direct evidence in this regard.  Indeed, work done by 
several investigators (26-28) shows that T  cells can recognize idiotypic determi- 
nants. 
Although other investigators (29, 30) have reported the induction of suppres- 
sive effects with immune spleen cells (presumably B cells), on antibody response 
to the helper T-cell-dependent antigen, SRBC, the mechanism(s) responsible for 
producing such suppression remain unclear. Here, one cannot ascribe such effects 
solely to the activation of suppressor T  cells by B-cell-associated antibody since 
suppression is believed to result from the interference of helper T  cell activity 
by suppressor T  cells; this process is H-2 restricted as well as allotype restricted. 
In contrast the antibody response to SSS-III does not require helper T  cells and 
is not influenced by genes linked to either the major (H-2) histocompatibility or 
IgCu  locus  (6).  In  this  regard  the  work of Braley-Mullen (31)  is  particularly 
significant. Using a system in which tolerance is induced by the administration 
of SSS-III  conjugated to  syngeneic spleen  cells, this  investigator showed that 
suppressor T  cells specific for SSS-III could be eliminated from cell suspensions 
by absorption to plates coated with anti-SSS-III antibody, a finding that supports 
our proposed hypothesis. The results of the present work (Table IV) also show 
that  immune  spleen  cells  required  for  the  induction  of suppression  can  be 
adsorbed to, and then eluted from, Sepharose 6MB columns to which SSS-III is 
bound covalently; cells not binding to the column were unable to induce sup- 
pression. 
Although the ability of amplifier T  cells to abrogate the suppression induced 
by immune B cells (Table VIII) once more illustrates the competitive nature of 
the interaction between suppressor and amplifier T  cells (1-6), the recognition 
unit(s) involved in the activation of amplifier T  cells remains to be defined. Two 
models have been proposed (7) that could explain how such interactions might 
occur; both are consistent with the results obtained in this work. In the competitive 
interaction model, both suppressor T  cells and amplifier T  cells possess receptors 
(antiidiotypic receptors) capable of recognizing the idiotypic determinant of cell- TAYLOR ET  AL.  715 
associated antibody on the surface of antigen-stimulated  (immune) B cells; thus, 
both types of regulatory T  cells can interact with a selected clone of B cells in a 
competitive manner.  However, in the dual inhibition  model, the idiotypic deter- 
minant common to cell-associated antibody specific for SSS-III is present on the 
surface of both antigen-stimulated  B cells and amplifier T  cells; since suppressor 
T  ceils possess a receptor capable of recognizing the idiotypic determinant,  they 
can  act to inhibit  the  functional  activity of both B  cells and  amplifier  T  cells. 
Sufficient  information  is  not  available  at  this  time  to  permit  one  to  decide 
between either of these possibilities. 
It has long been known that the antibody response to the capsular polysaccha- 
ride  of Streptococcus pneumoniae  provides  the  principal  means  for  conferring 
protective  immunity  against  virulent  pneumococci (32-36).  The  experimental 
model described in the present work, which deals with regulation of the antibody 
response to SSS-III, is the best documented--if not the only--one now in  use 
that  relates  directly  to  T  cell  regulatory  mechanisms  involved in  an  antibody 
response to a  microbial antigen.  Obviously, a  more complete understanding  of 
these  regulatory  processes is  likely to  increase  our  knowledge  concerning  the 
development  of effective  immunity  to  other  microbial  agents  of biomedical 
importance. 
Summary 
The transfer of B iymphocytes from mice immunized with type III pneumo- 
coccal  polysaccharide  (SSS-III)  results  in  antigen-specific  suppression  of  the 
antibody response of recipients immunized with SSS-III. Such suppression shares 
many  features  associated with  low-dose paralysis,  a  phenomenon  mediated  by 
suppressor T  cells; it reaches maximal  levels 3 d  after the transfer of viable or 
irradiated  immune  B  cells and  can  be eliminated  by the  depletion  of SSS-III- 
binding  cells  from  spleen  cell  suspensions  before  transfer.  In  a  two-step  cell 
transfer experiment, purified T  lymphocytes, isolated from recipients previously 
given immune B cells, caused suppression upon transfer to other mice immunized 
with SSS-III. Also, B-cell-induced suppression could be abrogated in a competi- 
tive  manner  by  the  infusion  of amplifier  T  lymphocytes,  as  was  previously 
demonstrated in the case of low-dose paralysis. These findings suggest that B cell 
surface  components,  presumably  the  idiotypic  determinants  of cell-associated 
antibody specific for SSS-III, are instrumental  in activating  suppressor T  cells 
involved in regulating the magnitude of the antibody response to SSS-III. 
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